Immunogenicity, Safety and Tolerability of Two Doses of a Pre-pandemic Influenza Vaccine in Participants Aged 6 Months to 17 Years
Immunogenicity, Safety and Tolerability of Two Doses of a Pre-pandemic Influenza Vaccine in Participants Aged 6 Months to 17 Years
Evaluate the immune response and reactogenicity of H5N1 vaccination in subjects aged 6 months
 to 17 years compared to seasonal flu vaccination
Inclusion Criteria:

 -  Healthy subjects

 Exclusion Criteria:

 -  Receipt of Seasonal Influenza Vaccine for season 2007/2008

 -  Receipt of another vaccine within 3 weeks before and after each vaccination

 -  Previous vaccination with a pandemic candidate vaccine and/or vaccine containing the
 adjuvant MF59 or a similar adjuvant

 -  Children who are in the local recommendation for influenza vaccination due to
 underlying diseases